Cells acquire cholesterol in part by endocytosis of cholesteryl ester containing lipoproteins. In endosomes and lysosomes cholesteryl ester is hydrolyzed by acidic cholesteryl ester hydrolase producing cholesterol and fatty acids. Under certain pathological conditions, however, such as in atherosclerosis, excessive levels of cholesteryl ester accumulate in lysosomes for reasons that are poorly understood. Here, we have studied endosomal and lysosomal cholesteryl ester metabolism in cultured mouse macrophages and with cell-free extracts. We show that net hydrolysis of cholesteryl ester is coupled to the transfer of cholesterol to membranes. When membrane cholesterol levels are low, absorption of cholesterol effectively drives cholesteryl ester hydrolysis. When cholesterol levels in acceptor membranes approach saturation or when cholesterol export is blocked, cholesterol is reesterified in endosomes. These results reveal a new facet of cellular cholesterol homeostasis and provide a potential explanation for cholesteryl ester accumulation in lysosomes of atherosclerotic cells.
. LDL and its atherogenic derivatives are recognized by cell surface receptors, internalized, and transferred to the endosomal system. Cholesteryl ester and triglycerides are then hydrolyzed by acidic cholesteryl ester hydrolase (aCEH), generating cholesterol and fatty acids (11, 13, 14) .
It has previously been proposed that lysosomal cholesteryl ester accumulation in atheromatous cells might result from a deficiency of aCEH (5, 15) . Most subsequent studies on aCEH activity in atherosclerotic biopsies have found, however, that aCEH levels were unchanged or increased (14) . Other hypotheses that have been proposed to explain the build-up of cholesteryl ester in lysosomes include esterification of cholesterol by a local enzyme (16) , saturation of aCEH with excessive substrate (15) , impaired delivery of aCEH to substrate-carrying endosomes (17) , and transport of ACAT-derived cholesteryl ester to lysosomes. Direct evidence in favor of any of these models, however, has not yet been available.
To further address this issue we have studied the metabolism of cholesteryl ester and triglycerides in mouse macrophages in vivo and with intact endosomes in vitro. We show that net hydrolysis of cholesteryl ester depends on the ability of membranes to absorb cholesterol. When membrane cholesterol approaches saturation, as it does in atherosclerosis, cholesterol is re-esterified in endosomes. Endosomal esterification occurs independently of canonical ACATs. Endosomal hydrolysis of triglycerides was not affected by cholesterol, indicating that activity and transport of aCEH remained unchanged. These findings reveal a feedback connection between cellular cholesterol balance and endosomal cholesterol dispensation and provide a potential explanation for why cholesterol-saturated cells in atherosclerotic lesions accumulate cholesteryl ester in lysosomes.
EXPERIMENTAL PROCEDURES Materials
We obtained egg yolk phosphatidylcholine (P-2772), dioleoylphosphatidylserine (P-1060), dicetyl phosphate, trioleoylglycerol (T-9275), cholesteryl oleate, 4-methylumbelliferyl Nacetyl-β-D-glucosaminide dihydrate, the sodium salt of adenosine 5′-monophosphate (A-1752), imipramine (I-0899), and progesterone (P-8783) from Sigma; U18666A from Biomol; 25-hydroxycholesterol from Steraloids; pepstatin A, leupeptin and the sodium salt of ATP from Roche Applied Science; [1, 2, 6, from PerkinElmer Life Sciences; wheat germ agglutinin-conjugated polyvinyltoluene (PVT) beads (RPNQ 0001) from Amersham Biosciences; FBS from Invitrogen; and other cell culture reagents from Mediatech. The ACAT inhibitor CI-976 was a gift from Pfizer Global Research and Development. The Rab5 antibody used in this study was a kind gift from A. Wandinger-Ness, University of New Mexico School of Medicine, Albuquerque, NM. Lipoprotein-deficient FBS (LPDS) (18) , LDL (18) , and acetylated LDL (19) were prepared as described. Anionic liposomes were prepared as described (20) and contained 1 mM phosphatidylcholine, 1 mM phosphatidylserine, 0.2 mM dicetyl phosphate plus neutral lipids as follows: liposomes prepared with [ gradient and quantified by an A 600 measurement using bead suspensions of known concentrations for calibration. Protein and phospholipids were quantified as described below.
Preparation of Phospholipid-covered PVT Beads
150 μl of 7% (w/v) wheat germ agglutinin PVT beads in water were mixed with 300 μl of hexane. Phosphatidylcholine (105 μg) and phosphatidylserine (113 μg) were added and the organic solvent dried under a stream of nitrogen gas. In some cases cholesterol was added at concentrations indicated in the figure legends. Beads were washed three times with cold PBS and resuspended in 250 μl of cold buffer E. Beads were quantified as described above. Protein and phospholipid were measured as described below.
In Vitro Acidic Hydrolysis and Esterification Assays
Unless otherwise stated, each reaction contained, in a final volume of 1 ml 250 mM sucrose, 125 mM KCl, 5 mM Mg/ml MgCl 2 , 2 mM EDTA, 10 μg/ml leupeptin, 5 μg/ml pepstatin A, J774 endosomes (35-75 μg of protein), and 20 mM sodium citrate (pH 4.5 reactions) or 50 mM Hepes-KOH (pH 7.5 control reactions). Reactions were carried out in siliconized 1.5-ml microcentrifuge tubes and terminated by transfer of tubes to ice. Immediately thereafter, samples were extracted twice with chloroform: methanol (95:5) and subjected to thin layer chromatography.
ACAT Assay
One confluent 10-cm dish of J774 cells was incubated for 6 h in medium A supplemented with 10% LPDS, liposomes (containing [ 3 H]cholesterol; 10 μCi/ml medium), 5 μg/ml 25-hydroxycholesterol, and 10 μM CI-976. Cells were then harvested, homogenized with a bent 22-gauge needle, and centrifuged at 1000 × g for 5 min. The resulting post-nuclear supernatant was centrifuged at 16,000 × g for 10 min. The membrane pellet was resuspended in 300 μl buffer F, pH 7.5, without oleoyl-CoA. ACAT activity was assayed in vitro as described (25) .
Lipid and Protein Analyses
To prepare whole-cell lipid extracts, cells were washed with PBS and lysed in 0.5% Nonidet P-40 plus protease inhibitors. Lipids were extracted with chloroform:methanol (95:5) and analyzed by thin layer chromatography.
To quantify tritiated cholesteryl ester and triglycerides, lipids were separated on silica gel G plates (Analtech) using hexane:ethyl ether: acetic acid (70:30:1) as the mobile phase. Plates were calibrated with authentic standards, and lanes were split into 16 fractions and analyzed by liquid scintillation counting.
To quantify [ 3 H]cholesterol and [ 3 H]cholesteryl ester, lipids were separated on silica gel LK5D plates (Whatman, 150-Å pores) using hexane:ethyl acetate (90:10) as the mobile phase. Lanes were split into eight fractions, scraped, and analyzed by liquid scintillation counting. Total phospholipids were measured as described (26) . Cholesterol was measured using an Amplex Red cholesterol assay kit (Molecular Probes). Protein was quantified using a bicinchoninic acid kit or with Coomassie Plus reagent (Pierce) using bovine serum albumin as a standard.
Immunoblot Analysis
Samples were separated by 12% SDS-PAGE, transferred to Hybond C-extra nitrocellulose (Amersham Biosciences) and blotted with anti-Rab5 antibody (1:3,000). Blots were then incubated with horseradish peroxidase-conjugated anti-mouse IgG (1:40,000; Jackson ImmunoResearch Laboratories), developed with Supersignal West Pico substrate (Pierce), and exposed to Kodak X-Omat Blue XB-1 film (PerkinElmer Life Sciences) at room temperature.
RESULTS

Reconstitution of Endosomal Cholesteryl Ester Hydrolysis in Vitro
To understand why atherosclerotic foam cells accumulate cholesteryl ester in lysosomes we started by setting up a system to study endosomal cholesteryl ester metabolism in vitro. The assay, described in the legend to Fig. 1 and in Table I , is based on the use of separately prepared cell fractions enriched for endosomes and plasma membrane, respectively. Endosomes were prepared from mouse J774 macrophages grown in the presence of liposomes containing [ 3 H] cholesteryl oleate plus non-radioactive trioleoylglycerol at 15 °C. Previous studies have shown that at this temperature, endocytosed lipoproteins accumulate in early endosomes and cholesteryl ester is hydrolyzed only to a small degree (27) . Similarly, we found that cholesteryl oleate delivered to J774 cells in liposomes for 4 h at 15 °C is hydrolyzed only by ~15% (data not shown). After sucrose gradient centrifugation, the bulk of the remaining esters can be collected from a sharp band that co-fractionates with the endosomal marker Rab5, well separated from the plasma membrane marker 5′-nucleotidase (Fig. 1A) . By analyzing the sedimentability of the soluble endosomal enzyme β-hexosaminidase we estimated that more than 90% of endosomal vesicles obtained by this method were intact and remained so during 2-h incubations at 37 °C (data not shown). Plasma membrane was purified by attachment to lectin-conjugated latex beads and equilibrium centrifugation and contained only small amounts of other organelles (Table I) .
To determine whether cholesteryl ester hydrolysis can be reconstituted with this material in vitro, [ 3 H]cholesteryl oleate-containing endosomes ("donors") were mixed with plasma membrane-covered beads ("acceptors") and incubated at pH 4.5. Subsequently, donor and acceptor membranes from each reaction were separated again by floating the plasma membrane-covered beads on sucrose gradients. Examination of the radioactive lipids showed a 64% reduction of [ 3 H]cholesteryl oleate levels and a concomitant increase of [ 3 H]cholesterol (Fig. 1B) . Significantly, 29% of the [ 3 H]cholesterol that was produced during 2-h incubations, but only trace amounts of [ 3 H]cholesteryl oleate, were transferred to acceptor membranes (Fig.  1B, right panel) . These results demonstrate that the in vitro system effectively reconstitutes hydrolysis of cholesteryl ester and that it allows for selective release of cholesterol. Hydrolysis was maximal at pH 4.5, and no activity was found with endosomes prepared from aCEHdeficient fibroblasts, indicating that hydrolysis under our assay conditions was catalyzed by aCEH (data not shown).
Increased Endosomal Cholesteryl Ester Hydrolysis in the Presence of Plasma Membrane
In previous studies with cultured cells it has been estimated that about 70% of cholesterol produced by endosomal hydrolysis of cholesteryl ester is transferred to the plasma membrane (28, 29) . Using our cell-free system we asked, therefore, whether the presence of plasma membrane fractions affects the degree and the kinetics of cholesteryl ester hydrolysis. When labeled endosomes were incubated without acceptors for 2 h, [ 3 H]cholesteryl oleate was reduced by 40% ( Fig. 2A) . Upon addition of increasing amounts of plasma membrane [ 3 H] cholesteryl oleate levels further decreased in a dose-dependent manner. Similar results were obtained with beads that had been covered with artificially prepared phospholipid membranes whereas naked beads were without effect (data not shown). Time curves for hydrolysis are shown in Fig. 2 , B and C. In the presence of plasma membrane, hydrolysis proceeded three times faster during the first 30 min of the reaction as compared with controls (Fig. 2B) . After 2 h, 40% of [ 3 H]cholesteryl oleate was hydrolyzed in the absence of acceptors, while 82% was hydrolyzed in their presence (Fig. 2C) .
The observation that synthetic phospholipid membranes stimulate endosomal cholesteryl ester hydrolysis suggests that the effect seen with plasma membrane fractions also results from the presence of phospholipids rather than addition of a neutral hydrolase or other protein factors. Further support for this conclusion comes from experiments showing that (i) hydrolysis was significantly more efficient at pH 4.5 than at pH 7.5 and (ii) at pH 7.5 plasma membrane fractions exhibited no hydrolytic activity toward cholesteryl ester in liposomes, while hydrolysis at this pH was efficient when microsomes were used (data not shown).
In summary, the results in Fig. 2 demonstrate that supplementary membranes promote net hydrolysis of cholesteryl ester. Since cholesterol is only poorly soluble in water (30) and a large fraction is selectively transferred to acceptors (Fig. 1C ) the simplest explanation for this effect is that membranes promote hydrolysis by removing cholesterol from the endosomal "equilibrium" of cholesteryl ester metabolism (31) . As one corollary of this model, the ratio of cholesterol to phospholipids in endosomal donors would be expected to remain constant. To test this prediction, [ 3 H]cholesteryl oleate-containing endosome fractions were incubated in the absence or presence of phospholipid-covered beads. Subsequently, the reaction mixtures were again separated to quantify [ 3 H]cholesterol, [ 3 H]cholesteryl ester, and phospholipids on donors and acceptors. Although the total amount of [ 3 H]cholesterol produced was significantly higher in the presence than in the absence of acceptors (Fig. 2D) , the [ 3 H]cholesterol-tophospholipid ratio in the two populations of donor membranes remained in fact the same (Fig.  2E ). The cholesterol difference was found quantitatively in the acceptor fraction, supporting the notion that the degree of net cholesteryl ester hydrolysis depends on the transfer of cholesterol to phospholipid membranes.
Modulation of Net Cholesteryl Ester Hydrolysis by Membrane Cholesterol Concentration
Studies with purified lipids in vitro have shown that the capacity of phospholipid bilayers for cholesterol becomes saturated at about 50 mol %. Above that concentration, crystals of cholesterol monohydrate begin to form and cholesterol saturation is thought to be responsible for cholesterol precipitation in advanced atherosclerotic lesions (6) . The plasma membrane fractions used in our experiments contained ~30% cholesterol with respect to phospholipids (Table II) , which explains why these membranes are still efficient at absorbing cholesterol ( To study the effect of increased membrane cholesterol on endosomal cholesteryl ester metabolism in vivo, J774 cells were grown for 4 h with increasing concentrations of acetylated LDL (AcLDL). As a consequence, the molar free cholesterol concentration with respect to phospholipids rose from 29% in controls to 39% in cells grown with 50 μg/ml of AcLDL and to 43% in cells grown with AcLDL plus the ACAT inhibitor CI-976 (Table II) (32) . Similar results were obtained with isolated plasma membrane fractions (Table II) .
In Fig. 3B J774 cells were loaded with cholesterol by incubation with AcLDL and CI-976 as described above. The cells were then washed and received [ 3 H]cholesteryl oleate in liposomes for 3 h at 15 °C. Preincubation with AcLDL had no effect on the uptake of liposomes (data not shown). But when cells were subsequently washed and moved to 37 °C, significantly more [ 3 H]cholesteryl oleate was found in cells that had been pre-loaded with AcLDL as compared with controls (Fig. 3B) . The increased cholesteryl ester levels found in response to AcLDL are unlikely to result from the action of ACAT as all incubations were performed in the presence of ACAT inhibitor. The drug effectively blocks ACAT both in cells and membrane extracts (Figs. 5 and 6, see below).
The results in Fig. 3, A and B, indicate that increased cholesterol concentrations in membranes reduce net hydrolysis of cholesteryl ester. To explain this effect, we next tested whether cholesterol loading might cause inhibition of aCEH. To address this possibility, we took advantage of the fact that aCEH is the sole enzyme responsible for endosomal hydrolysis of both cholesteryl ester and triglycerides (14) . If cholesterol affected the activity of aCEH, hydrolysis of liposome-derived triglycerides should also be reduced. However, preincubation of J774 cells with AcLDL had no effect on hydrolysis of [ 3 H]trioleoylglycerol (Fig. 3C) . As aCEH is thought to be monomeric with a single substrate-binding site (14, 33) , these data do not support the hypothesis that cholesterol modulates the activity of aCEH. They also rule out the possibility that high cholesterol levels might interfere with the movement of substrates to more acidic or aCEH-rich vesicles or that AcLDL loading might have overwhelmed the enzyme with excessive amounts of substrate. In summary, the data in Fig. 3 demonstrate that saturation of membranes with cholesterol reduces net hydrolysis of cholesteryl ester, apparently without affecting the activity of aCEH.
Cholesteryl Ester Synthesis in Endosomes
The next set of experiments was designed to test whether cholesterol-loaded cells synthesize cholesteryl ester in endosomes and lysosomes. In Fig. 4 Neutral ACAT enzymes can be ruled out as catalysts in the esterification reactions as the experiments in Fig. 4 , A and B, were performed at pH 4.5 in the presence of an ACAT inhibitor, conditions that effectively block microsomal cholesterol esterification activity even in extracts from cells that had been pre-treated with 25-hydroxycholesterol (Fig. 5A) , a potent activator of ACAT (10).
Contrary to results obtained with microsomes (25, (34) (35) (36) , addition of 25-hydroxycholesterol to endosomes in vitro at pH 4.5 or pH 7.5 had no effect on cholesterol esterification (data not shown).
Endosomal triglyceride hydrolysis and cholesterol esterification exhibit a clear maximum at pH 4.5 (Fig. 5B) . The peak at pH 4.5 for cholesteryl [ 3 H]oleate synthesis can in part be explained by the fact that aCEH-catalyzed hydrolysis is a prerequisite for esterification.
However, lowering the pH from 7.5 to 4.5 increased triglyceride hydrolysis 3-fold, while esterification was increased 22-fold, indicating that pH affects cholesteryl ester formation synergistically. Taken together, these results support the conclusion that cholesteryl ester synthesis during the in vitro reactions is catalyzed by an acidic endosomal enzyme.
In Fig. 4B endosomal cholesteryl (Fig. 6A) . In the absence of ACAT inhibitor, pretreatment with AcLDL increased cellular cholesteryl [ 3 H]oleate levels about 2-fold. In the presence of AcLDL plus ACAT inhibitor, cholesteryl [ 3 H]oleate levels were increased 40-fold compared with samples with ACAT inhibitor alone. Varying the AcLDL concentration indicated that ACATindependent cholesteryl [ 3 H]oleate synthesis was increased at AcLDL concentrations as low as 5 μg/ml (Fig. 6B) .
To determine the subcellular localization of the cholesteryl [ 3 H]oleate that accumulates in the presence of ACAT inhibitor, J774 cells were grown plus or minus AcLDL and then received liposomes containing [ 3 H]trioleoylglycerol and cholesteryl oleate as described above. ACAT inhibitor was present throughout the experiment. Cell homogenates were then subjected to sucrose gradient centrifugation and fractions were analyzed for organelle markers and radiolabeled lipids. Due to the presence of the ACAT inhibitor, only minimal quantities of cholesteryl [ 3 H]oleate were seen in the ER fractions under all conditions (Fig. 6C, upper  panel) . In lysosomes from cells grown with AcLDL, cholesteryl [ 3 H]oleate levels were 14-fold higher compared with the same fraction from control samples.
The results in Fig. 6 show that elevated cholesterol levels can promote cholesteryl ester synthesis in lysosomes of living cells, which mirrors the results we obtained with endosomes and cholesterol-saturated membranes in vitro (Fig. 4B) .
Inhibition of Cholesterol Transport Promotes Cholesteryl Ester Synthesis in Lysosomes in Vivo
The results in Figs. 3-6 show that endosomes esterify cholesterol when phospholipid acceptors are absent or when available membranes are saturated with cholesterol. These data support the conclusion that endosomal cholesteryl ester metabolism is coupled to the transfer of cholesterol to phospholipids. As another verification of this concept in vivo, we tested whether cholesteryl ester levels are increased when cholesterol export from the endosomal system is blocked pharmacologically.
In Fig. 7A J774 macrophages were initially starved for cholesterol and then loaded with [ 3 H] cholesteryl oleate plus unlabeled trioleoylglycerol at 15 °C to accumulate the esters in endosomes. The cells were then shifted to 37 °C in the absence or presence of the cholesterol transport inhibitor progesterone (37, 38) . At 3-10 μg/ml progesterone, cellular [ 3 H]cholesteryl ester levels were 50-75% higher as compared with controls (upper panel).
To rule out that progesterone treatment increased cholesteryl ester levels by reducing the activity of aCEH, cells were loaded with [ 3 H]trioleoylglycerol plus non-radioactive cholesteryl oleate and then incubated with progesterone as described above. As shown in Fig. 7B (upper panel), [ 3 H]triglyceride levels remained similar in the absence and presence of progesterone confirming that aCEH is unaffected by this drug. To determine whether cholesterol was reesterified in the presence of progesterone, the same extracts were then analyzed for the presence of radiolabeled cholesteryl ester. In response to progesterone, cholesteryl [ 3 H]oleate indeed increased in a dose-dependent manner (Fig. 7B, lower panel) . Taken together, the results in Fig. 7 are consistent with the conclusion that cholesterol export from the endosomal system is necessary for complete hydrolysis of cholesteryl ester. When export is blocked, cholesterol is actively re-esterified.
Both experiments in Fig. 7 were performed in the absence of an ACAT inhibitor as several studies have shown that progesterone blocks transport of cholesterol to the ER (37). To further verify whether cholesteryl ester synthesis can occur in endosomes we performed a series of experiments that are shown in Fig. 8 . First, J774 cells were allowed to endocytose [ 3 H] trioleoylglycerol together with non-radioactive cholesteryl oleate for 4 h. Some cells also received CI-976, progesterone, U18666A, or imipramine. U18666A and imipramine, similar to progesterone, block cholesterol release from lysosomes (37, 39, 40) . In the absence of cholesterol transport inhibitors, cholesteryl [ 3 H]oleate was produced and this was largely blocked by the ACAT inhibitor CI-976 (Fig. 8A, upper panel) . In the presence of progesterone, U18666A, or imipramine, however, cholesteryl [ 3 H]oleate levels remained high even in the presence of CI-976.
As a genetic approach to addressing a potential involvement of ACAT, we performed experiments with control 25RA and ACAT-deficient SRD-4 Chinese hamster ovary cells (41) (42) (43) . Here again, the absence of ACAT did not prevent U18666A-induced cholesteryl [ 3 H]oleate synthesis (Fig. 8B ). Fig. 8, A and B, indicates that the cholesterol transport inhibitors did not interfere with aCEH activity per se (lower panels). Inhibition of cholesteryl ester synthesis, however, consistently led to a compensatory increase of [ 3 H]triglyceride levels.
Inspection of [ 3 H]triglycerides in
To determine the subcellular localization of the cholesteryl [ 3 H]oleate that accumulates upon inhibition of cholesterol transport, J774 cells were incubated with [ 3 H]trioleoylglycerol and non-radioactive cholesteryl oleate plus or minus U18666A and ACAT inhibitor as described above. Cells were then fractionated by density gradient centrifugation to separate lysosomes from ER and cytosolic lipid droplets. In homogenates from control-treated cells, most of the cholesteryl [ 3 H]oleate was found in cytosolic lipid droplets and a sizable amount was found in the ER (Fig. 8C, upper panel) . In the presence of ACAT inhibitor, accumulation of cholesteryl [ 3 H]oleate in lipid droplets and in the ER was blocked as expected (10, 44) . Addition of U18666A also prevented accumulation of cholesteryl [ 3 H]oleate in lipid droplets and in the ER but led to a 10-18-fold increase of cholesteryl [ 3 H]oleate levels in lysosomes. In summary, the data in Figs. 7 and 8 demonstrate that pharmacological inhibition of cholesterol transport leads to ACAT-independent cholesterol esterification in lysosomes.
In Fig. 9 we asked whether lysosomal accumulation of cholesteryl ester in response to inhibition of cholesterol transport is reversible. J774 cells were allowed to accumulate cholesteryl [ 3 H] oleate in lysosomes after growth with non-radioactive cholesteryl oleate, [ 3 H]trioleoylglycerol, ACAT inhibitor, and imipramine. When imipramine was subsequently washed out, hydrolysis resumed and cholesteryl [ 3 H]oleate levels decreased by 96% after 4 h (Fig. 9, upper panel) . In cells that continued to grow in the presence of imipramine, cholesteryl [ 3 H]oleate levels remained high. [ 3 H]Triglycerides decreased with similar kinetics with or without imipramine, indicating that the intrinsic activity of aCEH remained unchanged (Fig. 9, lower panel) . In addition to demonstrating that cholesteryl [ 3 H]oleate accumulation in response to imipramine is reversible, these results provide an illustration for how cholesterol release from lysosomes promotes net hydrolysis of cholesteryl ester.
DISCUSSION
The current data support a model in which endosomal cholesteryl ester hydrolysis proceeds in two steps. Following transfer to the endocytic system, cholesteryl ester is initially hydrolyzed only to a point at which proximal endosomal membranes are saturated with cholesterol. At that stage, net cholesteryl ester hydrolysis stalls as cholesterol is re-esterified in endosomes. In a second step, transfer of cholesterol to extra-endosomal membranes drives cholesteryl ester hydrolysis to completion or to a stage at which these membranes, too, are saturated with cholesterol.
In support of this scheme, we found that isolated endosomes hydrolyzed cholesteryl ester only to a limited extent, whereas addition of cholesterol-poor membranes allowed selective cholesterol release and promoted cholesteryl ester reduction (Figs. 1 and 2) . Equivalent results were obtained in living cells; upon pharmacological inhibition of cholesterol export from lysosomes, cholesteryl ester levels remained high but then declined when the transport block was removed (Figs. 7 and 9 ).
Our studies indicate that, under physiological conditions, net hydrolysis of cholesteryl ester is determined by the cholesterol concentration in acceptor membranes. Overloading cells with cholesterol in the absence of serum and in the presence of an ACAT inhibitor reduced net hydrolysis of cholesteryl ester. Similarly, experiments with cell-free extracts demonstrated that endosomal cholesteryl ester levels remain high in the presence of membranes already saturated with cholesterol (Fig. 3) .
A number of papers reported increased cell death in macrophages exposed to modified lipoproteins for prolonged periods of time (45) (46) (47) . Under the conditions used here, however, no increased apoptosis was detected as judged by caspase activation (data not shown). (Figs. 4 and 5) . Saturation of membranes with cholesterol also led to a build-up of lysosomal cholesteryl [ 3 H] oleate in vivo (Fig. 6) . Whether cholesteryl ester sequestration under these conditions results from changes in cholesterol trafficking or whether the lysosomal cholesterol pool remains in dynamic equilibrium with other membranes remains to be determined.
Increased amounts of cholesteryl [ 3 H]oleate were synthesized in lysosomes of cells that had been grown in the presence of drugs that block the export of cholesterol from lysosomes, supporting the notion that endosomal cholesteryl ester metabolism is coupled to cholesterol release (Figs. 7-9 ). The current results on the effects of progesterone, U18666A, and imipramine might seem paradoxical in light of the fact that these drugs were described as cholesterol transport inhibitors based in part on their ability to cause the accumulation of unesterified cholesterol in lysosomes (37) . In these studies, cells were exposed to inhibitors for one to several days, while our experiments were terminated after 4 h. We noted that the synthesis of cholesteryl [ 3 H]oleate in the presence of cholesterol transport inhibitors started to diminish after about 8 h (data not shown), possibly because endosomes start to accumulate phospholipids, increasing their capacity for unesterified cholesterol.
The identity of the enzyme that is responsible for the endosomal acidic esterification activity we observed is currently unknown. The most well understood cellular cholesterol-esterifying enzyme is ACAT, which uses cholesterol and acyl-CoA as substrates. Two main isoforms have been described, ACAT1 and ACAT2 (34, 48) . In addition, a novel splice variant of human ACAT1 has recently been described whose biochemical characteristics have not yet been reported (49) . However, several lines of evidence support the conclusion that the cholesteryl [ 3 H]oleate synthesis we observed under the above-described conditions was not catalyzed by canonical ACAT. (i) In living cells, synthesis continued in ACAT-deficient cells and in the presence of an ACAT inhibitor (Figs. 6 and 8); (ii) the pH optimum for cholesteryl [ 3 H]oleate synthesis by endosomal fractions in vitro was 4.5 ( Fig. 5) , whereas the pH optimum for ACATs is above neutral (50); (iii) cholesteryl [ 3 H]oleate produced in vivo co-fractionated with endosomal/lysosomal vesicles (Figs. 6 and 8) , whereas ACAT resides predominantly in the ER and its products are released either into the cytoplasm or the ER lumen (44, (51) (52) (53) ; (iv) unlike ACAT (25, (34) (35) (36) , the acidic esterification activity was not stimulated by 25-hydroxycholesterol (data not shown).
The only acidic cholesterol-esterifying enzyme that has been described is aCEH, which in reversal of its well known hydrolytic activity can synthesize cholesteryl ester from cholesterol and fatty acids (14) . Previous studies with aCEH-deficient cell extracts have indicated that aCEH is the only acidic cholesterol-esterifying enzyme in human fibroblasts (54) . However, based on the current data, the existence of another acidic cholesterol-esterifying enzyme in macrophages or other cell types cannot be ruled out.
Effectively, the dependence of endosomal cholesteryl ester hydrolysis on the cellular cholesterol content can be regarded as another safeguard protecting cells against the potentially toxic effects of excess lipoprotein-derived cholesterol (47) . In the sequence of feedback responses that follows the cellular uptake of cholesteryl ester, endosomal cholesteryl ester retention is an early effect that may diminish over time as other mechanisms of cholesterol reduction take over (10, 55, 56) . However, cholesteryl ester does persist in lysosomes under certain conditions such as in atherosclerotic foam cells containing large quantities of cholesterol. Based on the current results, we propose that atheromatous cells accumulate cholesteryl ester in lysosomes due to local re-esterification of cholesterol.
Fig 1. Reconstitution of cholesteryl ester hydrolysis in endosomes in vitro
A, three confluent dishes of J774 mouse macrophages were incubated for 4 h at 15 °C in medium A supplemented with 10% LPDS plus liposomes (containing non-radioactive trioleoylglycerol and [ 3 H]cholesteryl oleate; 8 μCi/ml medium). Cells were fractionated by sucrose gradient centrifugation as described under "Experimental Procedures" (see "Protocol 1"). 13 fractions were collected and each analyzed for the activities of several markers. A, bars indicate total radioactivity and circles indicate the activity of 5′ nucleotidase (plasma membrane). The activity of NADPH-cytochrome c reductase (ER) peaked in fraction 1, and the activity of β-hexosaminidase (endo/lysosomes) peaked in fraction 7 (profiles not shown). The sucrose concentration in fraction 7 was 35%. In this and subsequent fractionation experiments, the activity of the plasma membrane marker 5′-nucleotidase in fraction 7 varied from 2-11% with a mean of 8%. Aliquots of fractions were also subjected to SDS-PAGE and blotted with an antibody against Rab5 (lower panel). B, J774 cells were labeled and fractionated as described for A. Plasma membrane fractions were prepared as described under "Experimental Procedures." Aliquots of endosomes (donors) containing non-radioactive trioleoylglycerol and [ 3 H]cholesteryl oleate (gradient fraction 7; 45 μg of protein/reaction) were incubated with plasma membrane fractions (acceptors, 20 μg of phospholipid) and 10 μM CI-976 at 37 °C for the indicated time. Donor and acceptor fractions were then separated on sucrose step gradients as described under "Experimental Procedures" (see "Protocol 2"). All incubations were at 37 °C. A, on day 0, J774 cells were set up in 6-well plates in medium A plus 10% FBS at 2.5 × 10 6 cells per well. On day 2, cells were switched for 4 h to medium A supplemented with 10% LPDS plus liposomes (containing non-radioactive cholesteryl oleate plus [ 3 H]trioleoylglycerol; 1 μCi/ml medium) in the absence or presence of 10 μg/ml progesterone, 2 μg/ml U18666A, 1.6 μg/ml imipramine, and 10 μM CI-976 as indicated. Proteins and lipids were analyzed as described under "Experimental Procedures." B, on day 0, 25RA-and ACAT-deficient SRD-4 cells were set up in 6-well plates in medium A containing 5% FBS at 5 × 10 6 cells per well. On day 1, cells were switched to 5% LPDS. On day 2, cells were incubated with 5 μg/ml LDL (reconstituted with non-radioactive cholesteryl oleate and [ 3 H]trioleoylglycerol; 34 nCi/μg protein) in the absence or presence of 2 μg/ml U18666A and 10 μM CI-976 as indicated. Cells were grown for 4 h, and proteins and lipids were analyzed as described above. C, J774 cells were set up as described for A and incubated in medium A supplemented with 10% LPDS, liposomes (containing non-radioactive cholesteryl oleate plus [ 3 H]trioleoylglycerol; 1 μCi/ml medium) plus or minus 2 μg/ml U18666A and 10 μM CI-976 as indicated. After 4 h at 37 °C, cell homogenates were fractionated as described under "Experimental Procedures" (see "Protocol 3"). Fractions were analyzed for organelle markers as described in the legend to Fig. 6 . β-Hex peaked in fractions 1 and 2 (containing 64% of the total β-hex activity and 17% of total CCR activity), CCR peaked in fractions 6-9 (containing 45% of total the CCR activity and 13% of total β-hex activity), and lipid droplets were in fractions 10-12 (containing 5% of total β-hex activity and 20% of CCR activity). The indicated pools were analyzed for protein concentration and lipids as described above. Upper panels, On day 0, J774 cells were set up in 6-well plates in medium A plus 10% FBS at 2.5 × 10 6 cells per well. On day 2, all wells were switched to medium A containing 10% LPDS, liposomes (containing non-radioactive cholesteryl oleate plus [ 3 H]trioleoylglycerol; 1 μCi/ml medium), 1.6 μg/ml imipramine, and 10 μM CI-976. Cells were incubated for 4 h at 37 °C, washed, and re-fed with medium A containing 10% LPDS and 10 μM CI-976 plus (filled circles) or minus (open circles) 1.6 μg/ml imipramine. At the indicated time, cells were harvested, and proteins and lipids were analyzed as described above. Upper panel, 
